Shares of InterMune Inc. rose at an intense speed on Wednesday. Intermune Inc. trades on the “NASDAQ” under the stock symbol “ITMN”. For the Latest information regarding “ITMN”, make sure to visit the Most Exclusive and In Depth newsletter website at: http://www.wallstreetgrand.com/.
Join today and be part of the best free investment newsletter on the web where we focus on market moving news.
Shares of InterMune Inc. (NASDAQ:ITMN) rose at an intense speed on Wednesday, a day after a federal advisory panel voted in favor of approval for its experimental lung disease treatment.
A Food and Drug Administration panel of lung experts voted 9 to 3 Tuesday to suggest approval of the drug Pirfenidone. The panel also voted 7 to 5 that the drug provides a "clinically meaningful benefit" for patients with idiopathic pulmonary fibrosis, an often fatal lung disease for which there are no approved drugs. The FDA is scheduled to make its final decision by May 4. It is not required to follow advisory panel advice, but it often does.
InterMune shares spiked $15.41, or 66 percent, to $38.71. The company is based in Brisbane, Calif.
You can contact us during market hours at 1-888-9-ClubGrand (1888-925-8247) or via email at staff@wallstreetgrand.com.
Safe Harbor
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act") including 2009 growth, revenue for the second quarter and year of 2009 and gross margin for the second quarter and year of 2009. Additionally, words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate" and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the impact of intense competition, the continuation or worsening of current economic conditions and the condition of the domestic and global credit and capital markets.
Disclaimer:
Wall Street Grand LLC has not been compensated by the company for this press release and does not expect to be compensated in the future for any type of awareness. To read our full disclaimer clicks the link http://www.wallstreetgrand.com/disclosure.html.
